ReviewJournal of clinical hypertension (Greenwich, Conn.)2006
The role of nitric oxide in erectile dysfunction: implications for medical therapy.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 193 citations in OpenAlex.
- Association between human immunodeficiency virus diagnosis and risk of penoscrotal conditions in adult males: A propensity-matched retrospective cohort study.BJUI compass · 2026Article
- Bridging fibrosis and function: an integrated mechanistic and therapeutic framework for Peyronie's disease and related erectile dysfunction.Sexual medicine · 2026Review
- Article
- Newly Diagnosed Diabetes Mellitus as an Etiology of Anejaculation and Primary Male Infertility: A Case Report and Review of the Literature.Journal of clinical medicine · 2026Review
- Omega-3 fatty acids attenuate alterations in penile erectile response by enhancing sexual behavior, nitric oxide-mediated signaling, and penile antioxidant status in tamoxifen-exposed rats.BMC pharmacology & toxicology · 2026Article
- Phytochemical-based nanomedicine as a promising therapeutic strategy for erectile dysfunction.Asian journal of andrology · 2026Review
- L-arginine attenuates cisplatin-induced sexual dysfunction in male Wistar rats by modulating circulating testosterone and NO/cGMP signaling.JBRA assisted reproduction · 2026Article
- Plant-derived bioactives in depression-related and antidepressant-associated sexual dysfunction: a narrative review.Frontiers in nutrition · 2026Review
- Article
- Interaction of the Gut-Liver-Brain Axis and the sterolbiome with sexual dysfunction in patients with cirrhosis.Gut microbes · 2025Review
- The relationship between vitamin D levels and erectile dysfunction: A mini-review.Clinical and experimental reproductive medicine · 2025Article
- Atherosclerosis-induced arterial erectile dysfunction: pathogenesis, diagnosis, and therapeutic strategies.Translational andrology and urology · 2025Review
- Lotus seed (Journal of traditional and complementary medicine · 2025Article
- Targeting TRPC-5 Channel Inhibition to Improve Penile Vascular Function in Erectile Dysfunction.International journal of molecular sciences · 2025Article
- Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status.Basic and clinical andrology · 2025Review
- From waste to health: exploring the male sexuality enhancing activities of the bioactive components of orange peel.Frontiers in endocrinology · 2025Review
- Resveratrol attenuates the priapism phenotype in sickle cell mice by restoring NO-cGMP-PDE5 signaling and reducing NADPH oxidase 2 expression.Frontiers in pharmacology · 2025Article
- Regulation of nitric oxide generation and consumption.International journal of biological sciences · 2025Review
- Correlation between Serum Levels of Nitric Oxide and Adropin and Erectile Dysfunction in Males with Nonalcoholic Fatty Liver Disease: An Observational Study.Reproductive sciences (Thousand Oaks, Calif.) · 2024Observational
- Estrogenic endocrine disruptor exposure directly impacts erectile function.Communications biology · 2024Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erectile dysfunction is a common, multifactorial disorder that is associated with aging and a range of organic and psychogenic conditions, including hypertension, hypercholesterolemia, diabetes mellitus, cardiovascular disease, and depression. Penile erection is a complex process involving psychogenic and hormonal input, and a neurovascular nonadrenergic, noncholinergic mechanism. Nitric oxide (NO) is believed to be the main vasoactive nonadrenergic, noncholinergic neurotransmitter and chemical mediator of penile erection. Released by nerve and endothelial cells in the corpora cavernosa of the penis, NO activates soluble guanylyl cyclase, which increases 3',5'-cyclic guanosine monophosphate (cGMP) levels. Acting as a second messenger molecule, cGMP regulates the activity of calcium channels as well as intracellular contractile proteins that affect the relaxation of corpus cavernosum smooth muscle. Impaired NO bioactivity is a major pathogenic mechanism of erectile dysfunction. Treatment of erectile dysfunction often requires combinations of psychogenic and medical therapies, many of which have been only moderately successful in the past. The advent of oral phosphodiesterase type 5 (PDE-5) inhibitors, however, has greatly enhanced erectile dysfunction treatment; patients have demonstrated high tolerability and success rates for improved erectile function. The efficacy of the PDE-5 inhibitors also serves to illustrate the importance of the NO-cGMP pathway in erectile function since these agents counteract the degradation of NO-generated cGMP. Because not all patients respond to PDE-5 inhibitors, additional therapies are being investigated, such as soluble guanylyl cyclase activators and NO donors, which act on NO-independent and NO-dependent pathways, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.